Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 181 to 195 of 1037 results for criteria

  1. Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (TA886)

    Evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults.

    Technology appraisal guidance
    Published
    10 May 2023
    View recommendations

    Sections for TA886

  2. Adalimumab for the treatment of adults with psoriasis (TA146)

    Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.

    Technology appraisal guidance
    Published
    25 June 2008
    View recommendations

    Sections for TA146

  3. Faricimab for treating wet age-related macular degeneration (TA800)

    Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Published
    29 June 2022
    View recommendations

    Sections for TA800

  4. Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)

    Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations in people 12 years and older.

    Technology appraisal guidance
    Published
    3 November 2021
    View recommendations

    Sections for TA742

  5. The role of primary care in supporting young people discharged from children's services:- What are the most effective ways for primary care services to be involved in planning and implementing transition, and following-up young people after transfer (whether or not they meet criteria for adult services)?

    and following-up young people after transfer (whether or not they meet criteria for adult services)? Any explanatory notes(if...

    Research recommendation
    Published
    21 March 2016

  6. Evidence summaries: unlicensed and off-label medicines – Integrated process statement (PMG14)

    Evidence summaries: unlicensed and off-label medicines – Integrated process statement

  7. Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)

    Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.

    Technology appraisal guidance
    Published
    15 November 2023
    View recommendations

    Sections for TA930

  8. Referral criteria for joint replacement: What are the most important indicators that someone with osteoarthritis (including shoulder osteoarthritis) would benefit from joint replacement? For example: - presence of night pain - non-response to non-pharmacological interventions - joint instability symptoms - presence of flares - numerical summary scores.

    Recommendation ID NG226/12 Question Referral criteria for joint replacement: What are the most important indicators that someone with...

    Research recommendation
    Published
    7 November 2022

  9. NICE encourages further research into focal cryoablation for localised prostate cancer. This should take the form of controlled studies comparing the procedure against other forms of management. Studies should clearly define patient selection criteria and should report outcomes including local recurrence in the long term.

    other forms of management. Studies should clearly define patient selection criteria and should report outcomes including local...

    Research recommendation
    Published
    9 June 2015

  10. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)

    Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    10 May 2023
    View recommendations

    Sections for TA887

  11. Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

    Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults.

    Technology appraisal guidance
    Published
    23 July 2014
    View recommendations

    Sections for TA319

  12. Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)

    Evidence-based recommendations on pomalidomide (Imnovid) for multiple myeloma previously treated with lenalidomide and bortezomib in adults.

    Technology appraisal guidance
    Published
    11 January 2017
    View recommendations

    Sections for TA427

  13. Headaches in over 12s (QS42)

    This quality standard covers diagnosing and managing common types of headache in adults and young people (aged 12 and over). It includes tension-type headache, migraine, cluster headache and medication overuse headache. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    28 August 2013
    View quality statements

    Sections for QS42

  14. Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy (TA895)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.

    Technology appraisal guidance
    Published
    7 June 2023
    View recommendations

    Sections for TA895

  15. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)

    Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.

    Technology appraisal guidance
    Published
    24 November 2010
    View recommendations

    Sections for TA208